TSE:4528Pharmaceuticals
Ono Pharmaceutical (TSE:4528) Could Be 33% Undervalued As Opdivo And Pipeline Progress Build
Ono Pharmaceutical (TSE:4528) moved sharply on the back of regulatory progress for Opdivo, pipeline updates around Velexbru and Qinlock, and encouraging mid stage trial data that reinforced interest in its cancer and rare disease portfolio.
See our latest analysis for Ono Pharmaceutical.
Against this backdrop, Ono Pharmaceutical’s share price has a 10.5% 1 month share price return and a 12.3% year to date share price return, while its 1 year total shareholder return of 65.0% points to strong...